Sézary T-cell-activating factor induces functional interleukin 2 receptors on T-cells derived from patients with Sézary syndrome.
Sézary syndrome is the leukemic form of cutaneous T-cell lymphoma characterized by circulating neoplastic CD4+ T-cells. Although peripheral blood mononuclear cells from patients with Sézary syndrome have been shown to respond poorly to mitogens, we found that mitogen-activated peripheral blood mononuclear cells from four of five patients with Sézary syndrome produce a 28 kDa protein termed Sézary T-cell activating factor (SAF). SAF renders nonproliferating "resting" T-cells from leukemic patients or healthy donors responsive to interleukin 2 in the absence of a costimulator. We demonstrate that SAF induces functional, high-affinity interleukin 2 receptors on T-cells from Sézary syndrome patients and provide evidence that SAF may be a novel cytokine.
Abrams
J T
JT
Department of Medicine, University of Miami School of Medicine, Florida 33101.
Ghosh
S K
SK
DeFreitas
E
E
D004591:Electrophoresis, Polyacrylamide Gel; D006801:Humans; D007375:Interleukin-1 / Q000302:isolation & purification / Q000494:pharmacology*; D007376:Interleukin-2 / Q000494:pharmacology; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism; D015375:Receptors, Interleukin-2 / Q000187:drug effects / Q000378:metabolism*; D011994:Recombinant Proteins / Q000494:pharmacology; D012751:Sezary Syndrome / Q000378:metabolism*; D012878:Skin Neoplasms / Q000378:metabolism*; D013601:T-Lymphocytes / Q000737:chemistry / Q000378:metabolism*
D007375:Interleukin-1; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D011994:Recombinant Proteins